BridgeBio Pharma (BBIO) Free Cash Flow (2018 - 2026)
BridgeBio Pharma (BBIO) posted Free Cash Flow of -$197.3 million for Q1 2026, down 243.18% sequentially from -$57.5 million in Q4 2025, and up 0.95% YoY from -$195.5 million in Q1 2025.
BridgeBio Pharma (BBIO) Free Cash Flow (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Free Cash Flow for 9 years, with the latest figure at -$197.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 0.95% year-over-year to -$197.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$445.1 million (up 10.98% YoY) and the FY2025 annual result came in at -$447.0 million, up 14.2% from the prior year.
- Free Cash Flow declined to -$197.3 million in Q1 2026 per BBIO's latest filing, from -$57.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $75.3 million in Q2 2024 and troughed at -$220.2 million in Q1 2024.
- A 5-year average of -$124.6 million and a median of -$132.0 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 245.17% in 2023, then surged 166.2% in 2024.
- Over 5 years, Free Cash Flow stood at -$98.0 million in 2022, then declined by 27.27% to -$124.7 million in 2023, then slumped by 56.61% to -$195.3 million in 2024, then soared by 70.56% to -$57.5 million in 2025, then slumped by 243.18% to -$197.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$197.3 million, -$57.5 million, and -$109.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | -71.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71.54 Mn |
| Jun 30, 2026 | -71.54 Mn |
| Mar 31, 2026 | -197.35 Mn |
| Mar 31, 2026 | -197.35 Mn |
| Dec 31, 2025 | -57.51 Mn |
| Dec 31, 2025 | -57.51 Mn |
| Sep 30, 2025 | -109.59 Mn |
| Sep 30, 2025 | -109.59 Mn |
| Jun 30, 2025 | -80.68 Mn |
| Jun 30, 2025 | -80.68 Mn |
| Mar 31, 2025 | -199.24 Mn |
| Mar 31, 2025 | -199.24 Mn |
| Dec 31, 2024 | -195.33 Mn |
| Dec 31, 2024 | -195.33 Mn |
| Sep 30, 2024 | -180.77 Mn |
| Sep 30, 2024 | -180.77 Mn |
| Jun 30, 2024 | 75.33 Mn |
| Jun 30, 2024 | 75.33 Mn |
| Mar 31, 2024 | -220.23 Mn |
| Mar 31, 2024 | -220.23 Mn |